BIOLASE Inc. (NASDAQ:BIOL) went down by -3.79% from its latest closing price compared to the recent 1-year high of $1.51. The company’s stock price has collected -7.60% of loss in the last five trading sessions. Press Release reported on 03/30/21 that BIOLASE Announces Collaboration with Einstein Healthcare Network’s Residency in Endodontics
Is It Worth Investing in BIOLASE Inc. (NASDAQ :BIOL) Right Now?
Plus, the 36-month beta value for BIOL is at 1.50. Opinions of the stock are interesting as 4 analysts out of 4 who provided ratings for BIOLASE Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $1.94. BIOL currently public float of 91.52M and currently shorts hold a 10.36% ratio of that float. Today, the average trading volume of BIOL was 30.46M shares.
BIOL’s Market Performance
BIOL stocks went down by -7.60% for the week, with a monthly jump of 5.73% and a quarterly performance of 68.72%, while its annual performance rate touched 237.45%. The volatility ratio for the week stands at 4.29% while the volatility levels for the past 30 days are set at 7.88% for BIOLASE Inc.. The simple moving average for the period of the last 20 days is -14.44% for BIOL stocks with a simple moving average of 44.71% for the last 200 days.
Analysts’ Opinion of BIOL
Many brokerage firms have already submitted their reports for BIOL stocks, with The Benchmark Company repeating the rating for BIOL by listing it as a “Speculative Buy.” The predicted price for BIOL in the upcoming period, according to The Benchmark Company is $2 based on the research report published on June 19th of the previous year 2019.
Singular Research, on the other hand, stated in their research note that they expect to see BIOL reach a price target of $2.50. The rating they have provided for BIOL stocks is “Buy” according to the report published on April 25th, 2017.
WallachBeth gave a rating of “Hold” to BIOL, setting the target price at $2.50 in the report published on May 13th of the previous year.
BIOL Trading at -23.51% from the 50-Day Moving Average
After a stumble in the market that brought BIOL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.48% of loss for the given period.
Volatility was left at 7.88%, however, over the last 30 days, the volatility rate increased by 4.29%, as shares sank -8.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.75% lower at present.
During the last 5 trading sessions, BIOL fell by -7.60%, which changed the moving average for the period of 200-days by +61.31% in comparison to the 20-day moving average, which settled at $0.9229. In addition, BIOLASE Inc. saw 90.30% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BIOL starting from FEINBERG LARRY N, who sale 1,770,312 shares at the price of $0.55 back on Jun 09. After this action, FEINBERG LARRY N now owns 0 shares of BIOLASE Inc., valued at $976,010 using the latest closing price.
FEINBERG LARRY N, the 10% Owner of BIOLASE Inc., sale 3,402,938 shares at $0.55 during a trade that took place back on Jun 08, which means that FEINBERG LARRY N is holding 264,141 shares at $1,885,908 based on the most recent closing price.
Stock Fundamentals for BIOL
Current profitability levels for the company are sitting at:
- -81.37 for the present operating margin
- +27.10 for the gross margin
The net margin for BIOLASE Inc. stands at -73.88. The total capital return value is set at -80.38, while invested capital returns managed to touch -104.10. Equity return is now at value -770.10, with -64.40 for asset returns.
Based on BIOLASE Inc. (BIOL), the company’s capital structure generated 179.10 points at debt to equity in total, while total debt to capital is 64.17. Total debt to assets is 43.78, with long-term debt to equity ratio resting at 181.23. Finally, the long-term debt to capital ratio is 64.17.
When we switch over and look at the enterprise to sales, we see a ratio of 1.13, with the company’s debt to enterprise value settled at 0.70. The receivables turnover for the company is 3.85 and the total asset turnover is 0.62. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.13.